StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)

Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%

Immunocore gross margin

Gross margin is gross profit as a percentage of revenue.

Immunocore's gross margin for the twelve months ending Sep 30, 2026 was 98.9%. For fiscal 2025 it was 98.7%, against 99.1% the year before. The highest annual figure on record is 100.0% in fiscal 2021.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202598.7%−0.4
FY2024Dec 31, 202499.1%−0.5
FY2023Dec 31, 202399.6%+0.2
FY2022Dec 31, 202299.4%−0.6
FY2021Dec 31, 2021100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202699.3%−0.2
Q2 FY2026Jun 30, 202699.1%+0.1
Q1 FY2026Mar 31, 202699.6%+0.5
Q4 FY2025Dec 31, 202597.4%−2.2
Q3 FY2025Sep 30, 202599.5%+0.1
Q2 FY2025Jun 30, 202598.9%+1.2
Q1 FY2025Mar 31, 202599.1%−0.5
Q4 FY2024Dec 31, 202499.6%−0.1
Q3 FY2024Sep 30, 202499.4%−0.1
Q2 FY2024Jun 30, 202497.7%−1.7
Q1 FY2024Mar 31, 202499.7%+0.0
Q4 FY2023Dec 31, 202399.7%–
Q3 FY2023Sep 30, 202399.6%–
Q2 FY2023Jun 30, 202399.4%–
Q1 FY2023Mar 31, 202399.6%–

More Immunocore figures

See a number that looks wrong?